ChromaDex price target raised to $8 from $6 at Roth MKM

Roth MKM raised the firm’s price target on ChromaDex (CDXC) to $8 from $6 and keeps a Buy rating on the shares. The company’s Q3 results handily beat estimates and demonstrate progress in pursuing new verticals targeted earlier in 2024, including Niagen+, Ataxia, and Parkinson’s, the analyst tells investors in a research note. The firm adds that it has greater confidence now in the company’s ability to capitalize on these opportunities.